EAN 2023 | Alleviating non-motor fluctuation-related pain in Parkinson’s through the OCEAN trial

In this interview, Prof. K. Ray Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK delves into the OCEAN trial, which aims to alleviate non-motor fluctuation-related pain in individuals living with Parkinson’s disease (PD) by utilizing opicapone, a novel catechol-O-methyltransferase inhibitor. Despite the challenges posed by the COVID-19 pandemic, the trial has persevered and is now in its final recruitment phase, due to the invaluable support of their colleagues in Poland. The eagerly anticipated results from the OCEAN trial are expected to be published at the latest by early next year and potentially be the first-ever trial to address pain, a significant non-motor issue in PD. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.